1. Introduction {#s0005}
===============

Cholestatic liver injury comprises a wide range of genetic or acquired disorders of bile formation and/or flow ultimately resulting in intrahepatic and systemic accumulation of bile salts (BSs) ([@b0935; @b1330]). Primary or secondary dysfunctions of specific hepatocellular transport systems as well as mechanical obstruction/destruction of the bile duct system are central mechanisms causing impaired elimination of biliary constituents. Elevated levels of BSs may cause liver damage due to their lipid solubilizing, proinflammatory and proapoptotic properties ([@b0020; @b0355; @b0500; @b0510; @b0780; @b1280]). Since intracellular BS content is regulated by complex mechanisms involving BS uptake, synthesis, detoxification and export, transcriptional stimulation or inhibition of specific transport mechanisms may be critical in limiting intrahepatic retention of BSs and hepatocyte damage. The canalicular BS export pump (BSEP), basolateral efflux transporter organic solute transporters alpha and beta (OSTα/OSTβ) as well as the BS uptake system Na^+^-taurocholate cotransporting polypeptide (NTCP) are the major regulators of intracellular BS load and have emerged as promising drug targets in cholestasis.

2. Functional role of BSEP in health and disease {#s0010}
================================================

Canalicular excretion of BSs constitutes the rate-limiting step in hepatic BS excretion and represents the driving force for their enterohepatic circulation ([@b1440]). BSEP (ABCB11), previously also known as sister of p-glycoprotein (sPgp) is a member of the canalicular ATP-binding cassette (ABC) transporter superfamily and represents the major canalicular BS export system ([@b0245; @b0450; @b1110; @b1440]). Conjugated monovalent BSs are the major substrate for BSEP ([@b0185; @b0450; @b0550; @b1125; @b1450]), among which taurochenodeoxycholic acid (TCDCA) is the preferred substrate followed by taurocholic acid (TCA), tauroursodeoxycholic acid (TUDCA) and glycocholic acid (GCA) ([@b1125]).

Various *BSEP* mutations differently impact on transporter activity leading to a wide variety of clinical manifestations in humans ([@b0590; @b0690]). Complete loss of function *BSEP* mutations manifest as severe cholestasis in progressive familial intrahepatic cholestasis type 2 (PFIC2) ([@b0655; @b1460; @b1465]) and patients carry a considerable risk for development of hepatobiliary malignancies ([@b0755; @b0760; @b1325; @b1345; @b1465]) likely due to persistent cell injury by elevated concentrations of intracellular BSs and impairment of cell repair mechanisms ([@b0760; @b1160; @b1390; @b1415]). In contrast, *BSEP* variants with mildly impaired transporter function manifest in form of benign recurrent intrahepatic cholestasis type 2 (BRIC2) ([@b0805; @b1545]) and may have a pathogenetic role in acquired cholestatic syndromes such as intrahepatic cholestasis of pregnancy (ICP) and drug-induced liver injury (DILI) ([@b0315; @b0330; @b0725; @b0805; @b0870; @b1020; @b1200; @b1545]). Although BSEP is critical for the maintenance of biliary BS excretion and protection against intrahepatic BS accumulation in humans, *BSEP* deficiency in mice causes only mild and non-progressive cholestasis with 30% preserved biliary BS output (mainly as tetra-hydroxylated BSs). It is important to note that in addition to BSEP, canalicular transporters such as the multidrug resistance protein 1 (MDR1/ABCB1), the multidrug resistance-associated protein 2 (MRP2/ABCC2) and the breast cancer resistance protein (BCRP/ABCG2) may also mediate canalicular export of sulfated bivalent and unusual tetra-hydroxylated BSs ([@b0015; @b0660; @b0735; @b0845; @b1030; @b1580]) accounting for partially preserved biliary BS elimination in rodents.

In addition to genetic *BSEP* variants, BSEP represents a vulnerable target for inhibition by various endogenous hormones/metabolites, inflammation or drugs resulting in acquired cholestasis such as ICP, DILI, sepsis/endotoxin-induced cholestasis and cholestasis caused by total parenteral nutrition (TPN). The pathogenesis of ICP is complex, but hypersensitivity to female hormones or their metabolites is likely to be involved ([@b0065]). Inhibition of *BSEP* gene transcription by β-estradiol or inhibition of its functional activity through trans-inhibition and internalization by the estrogen metabolite estradiol-17β-glucuronide ([@b0270; @b0455; @b1450]) are important mechanisms predisposing to estrogen-induced cholestasis ([@b0135; @b1645]). Apart from female hormones, drugs such as cyclosporine, glibenclamide, rifamycin SV, rifampicin, indomethacin and bosentan ([@b0185; @b0350; @b0385; @b1070; @b1125; @b1135; @b1435; @b1450]) or constituents of TPN solutions ([@b0930; @b1120]) may also inhibit BSEP-mediated BS export through either competitive inhibition ([@b1450]) or through mechanisms involving MRP2-dependent stimulation of BS-independent bile flow ([@b0385]).

Notably, genetic or acquired BSEP dysfunction is also likely to predispose to biliary cholesterol precipitation, since biliary BSs are essential for cholesterol solubilization in bile. This may explain the high prevalence of gallstone disease (32%) in PFIC2 patients ([@b1210]). In support of this hypothesis, patients with cholesterol gallstones show low expression of the *BSEP* upstream regulator farnesoid X receptor (*FXR*/*NR1H4*) ([@b0155]) and its coactivator peroxisome proliferator-activated receptor gamma coactivator-1 alpha (*PGC-1α* ([@b1690]), whereas FXR activation prevents gallstone formation in mice ([@b1080]). In addition, reduced efflux of biliary BSs may lead to malabsorption of fat and fat-soluble vitamins and subsequently impair whole body energy homeostasis. Indeed, children with PFIC2 developed severe steatorrhoea ([@b1570]), whereas *BSEP* overexpression increased dietary cholesterol and fatty acid absorption and promoted development of diet-induced obesity in mice ([@b0575; @b1605]). Finally, altered biliary BS elimination may have multiple extrahepatic implications, which may be attributed to the emerging key role of BSs in lipid, glucose and energy homeostasis ([@b1520; @b1515; @b1590; @b1615]). Taken together, targeting mechanisms promoting BSEP-mediated BS export can be expected to have beneficial effects in cholestatic liver injury and its extrahepatic complications.

3. Transcriptional regulation of BSEP {#s0015}
=====================================

Regulation of BSEP-mediated BS efflux is complex and involves transcriptional as well as posttranscriptional mechanisms (the latter discussed in chapter by J.L. Boyer). The nuclear BS receptor FXR acts as the major stimulator of *BSEP* transcription in humans, mice and rats through its heterodimerization with the retinoid X receptor alpha (RXRα) and binding to the FXR response element (FXRE), inverse repeat 1 (IR-1), in the *BSEP* promoter ([@b0035; @b0455; @b1220]). BS-mediated *BSEP* expression is likely to be influenced by intracellular BS flux rather than steady state concentrations ([@b1625]) and differs dependent on the ability of endogenous BSs to activate FXR. Notably, chenodeoxycholic acid (CDCA), deoxycholic acid (DCA) and cholic acid (CA) are strong FXR activators ([@b0955; @b1170; @b1575]), whereas the less potent FXR activator litocholic acid (LCA) even inhibited FXR-mediated *BSEP* transactivation by endogenous and synthetic FXR ligands (CDCA and GW4064 respectively) ([@b1680]). Importantly, murine-specific primary BSs α- and β-tauromuricholic acid (TαMCA and TβMCA) were also identified as FXR antagonists and may be responsible for lower expression of FXR target genes in ileum of germ-free mice ([@b1320]). Furthermore, TβMCA biotransformation by gut microbiota may significantly influence BS synthesis as well as transport through mitigation of TβMCA-mediated FXR inhibition in gut ([@b1320]).

Recent studies identified the role of several nuclear receptor co-activating proteins as important mediators of FXR-mediated *BSEP* transcription. In particular, the key regulator of energy homeostasis PGC-1α and components of the activating signal cointegrator-2-containing complex (ASCOM) interact with FXR to enhance FXR-dependent *BSEP* expression in a ligand-dependent manner ([@b0045; @b0700; @b1315]). Importantly, recruitment of the ASCOM complex components to the *BSEP* promoter was disrupted in cholestasis induced by common bile duct ligation (CBDL) ([@b0045]). This could provide a plausible explanation for paradoxal lack of *BSEP* induction in cholestasis, despite potential BS-dependent FXR activation by accumulating intrahepatic BSs. In addition, secondary co-activators such as co-activator-associated arginine methyltransferase 1 (CARM1) ([@b0895]) and direct methylation of FXR by Set7/9 methyltransferase facilitate FXR/RXRα-dependent *BSEP* transcription ([@b0040; @b0100]). The recent discovery of FXR-mediated *BSEP* regulation through recruitment of a transcription co-activator, steroid receptor co-activator 2 (SRC2), provides a novel mechanistic link between intracellular energy depletion and fat absorption. Hepatocyte-specific *SRC2*^−/−^ mice showed reduced *BSEP* gene expression and developed signs of cholestasis such as increased intrahepatic and serum BS levels and impaired dietary fat absorption, while dietary CA supplementation or restoration of hepatic *BSEP* expression by adenoviral vector rescued cholestatic phenotype in these mice ([@b0255]). Since SRC2 is phosphorylated and activated by the intracellular energy sensor AMP-activated protein kinase (AMPK), this study provided a novel functional crosstalk between hepatic energy depletion and FXR-mediated BS secretion to promote dietary fat absorption and further emphasizes the key role of BSEP in lipid metabolism ([@b0255]). In line with these findings, AMPK activation is directly involved in formation and maintenance of the hepatocyte canalicular network ([@b0395]). Thus, AMPK activators such as the antidiabetic drug metformin and the antiischemic drug 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) may -- apart from their direct action on intracellular metabolism -- also have indirect beneficial effects through regulation of biliary BS secretion and promotion of cellular energy supplementation by BSs. In addition, AMPK activators are likely to have cytoprotective effects through promotion of AMPK--SRC2--BSEP-mediated elimination of BSs.

Apart from FXR, several other transcriptional factors also target *BSEP* gene expression. The human and mouse *BSEP* promoters contain a response element for the liver receptor homologue 1 (LRH1/NR5A2) ([@b1400]), an essential regulator of development, metabolism and BS synthesis ([@b0360]). LRH-1 mediates CDCA- or FXR-dependent maximal *BSEP* transcription, whereas its loss markedly reduces expression of hepatobiliary transporters *BSEP*, *NTCP*, *MRP2* and multidrug resistance-associated protein 3 (*MRP3*/*ABCC3*) as well as nuclear receptors *FXR* and short heterodimer partner (*SHP*/NR0B2) ([@b0905; @b0985]). Interestingly, the FXR target SHP negatively regulates LRH-1-mediated *BSEP* transactivation ([@b0740]), a finding that appears inconsistent with BS-FXR-dependent induction of *BSEP*. However, *BSEP* is a direct target of FXR and LRH-1, and therefore, FXR- or LRH-1-mediated induction is likely to dominate over BS-SHP-mediated repression ([@b1400]). Since phospholipids (PLs) bind LRH-1 ([@b0795; @b1150]), they could in addition to their protective role against biliary BS toxicity ([@b0265; @b1380]) also reduce intracellular BS toxicity through promotion of LRH-1-mediated canalicular export. In support of this assumption, dietary lecithin was protective in mice lacking the canalicular PL exporter multidrug resistance protein 2 (MDR2/ABCB4, human orthologue of MDR3) after dietary CA supplementation ([@b0850]), but had no effects on development of spontaneous liver injury without BS challenge in this model ([@b0085]). Another important protective mechanism against BS toxicity is the upregulation of *BSEP* as part of the primary cell response to oxidative stress. Nuclear factor erythroid 2-related factor 2 (NRF2) mediates antioxidative defense through heterodimer formation with musculo-aponeurotic fibrosacroma (MAF) protein and binding to the MAF recognition element (MARE) in the promoter of target genes ([@b0650]). Two MAREs were identified in the human *BSEP* promoter and mutations of the predicted MARE1 region abolished *BSEP* induction by a potent NRF2 activator oltipraz ([@b1620]). Thus, in addition to direct anti-oxidative effects, NRF2 activators may diminish liver injury through canalicular elimination of potentially toxic BSs. Apart from the above mentioned mechanisms, *BSEP* transcription is also induced by ligands of the pregnane X receptor (PXR/NR1I2) ([@b1505]), whereas several *in vitro* studies reported controversial effects on the glucocorticoid receptor (GR/NR3C1). Although the GR agonist dexamethasone was essential for *BSEP* expression in cultured rat primary hepatocytes ([@b1610]), it failed to induce *BSEP* expression in sandwich cultured cells forming functional canalicular units ([@b1540]).

Importantly, *BSEP* transcription is negatively regulated in pathological conditions such as inflammation or drug toxicity. A clear decrease of peri-portal BSEP was detected in CBDL- and lipopolysaccharide (LPS)-induced liver injury, whereas peri-central expression remained unchanged ([@b0325]). BSEP restoration after blockade of tumor necrosis factor alpha (TNF-α or interleukin-1 beta (IL-1β (by etanercept or anakinra respectively) in models of CBDL-, LPS- and TPN-induced liver injury established a pathogenetic role of inflammatory cell-derived cytokines for *BSEP* inhibition ([@b0210; @b0325; @b0930]). In support of this hypothesis, TNF-α, IL-1β and interleukin-6 (IL-6) reduced *BSEP* gene expression in human sandwich-cultured hepatocytes ([@b0310]). Reduced binding of FXR/RXRα heterodimer to IR-1 ([@b0430]a) and direct interaction of the nuclear factor kappa-B (NF-κB) subunits with FXR ([@b0405]) are the main mechanisms mediating cytokine-dependent *BSEP* inhibition. In addition, cytokines caused down-regulation of RXRα, an obligate partner for heterodimer formation with the major *BSEP* stimulator FXR and PXR ([@b0145; @b0150; @b1185; @b1505]). Notably, hepatotoxic effects of the antidiabetic drug troglitazone (agonist of peroxisome proliferator-activated receptor gamma (PPARγ)) are mediated through stable complex formation with the FXR ligand binding domain and suppression of FXR-mediated *BSEP* transactivation ([@b0695]). However, this effect of troglitazone was PPARγ-independent as other PPARγ activators did not interfere with FXR activity.

4. Functional role of OSTα/OSTβ in health and disease {#s0020}
=====================================================

In addition to canalicular BS export, retrograde elimination/overflow of BSs into sinusoidal blood through basolateral efflux transporters represents an alternative rescue mechanism to reduce intracellular BS load. This process is mediated by several transport proteins with wide substrate specificity, such as the organic solute transporter (OST/SLC51), MRP3 and multidrug resistance-associated protein 4 (MRP4/ABCC4). Although MRP3 and especially MRP4 are induced and play a protective role in cholestasis ([@b1025; @b1685]), MRP4 is likely to be regulated mainly at the posttranscriptional level ([@b0295]). In contrast, transcriptional upregulation of OST is even more pronounced ([@b1555; @b1715]), indicating that adaptive upregulation of OST may be the predominant mechanism of basolateral BS elimination. OST is composed of 2 proteins -- OSTα and OSTβ -- ([@b1585]) and is expressed on the basolateral surface of cell populations critically involved in BS transport/reabsorption: enterocytes, hepatocytes, bile duct lining cells -- cholangiocytes and tubular renal cells ([@b0110; @b0285; @b1265]). OSTα/OSTβ expression in hepatocytes enables BS elimination into blood sinusoids, whereas in enterocytes it is critical for intestinal BS absorption and their enterohepatic circulation. Its expression in cholangiocytes serves cholangiocellular transport and intrahepatic recycling of BSs. Apart from BSs OSTα/OSTβ also mediates transport of molecules such as estrone 3-sulfate, dehydroepiandrosterone, digoxin and prostaglandine E2 ([@b0105; @b0110; @b0290; @b1335]). Importantly, in contrast to humans, OSTα/OSTβ expression is very low in mouse liver ([@b0110; @b0285]). Although hepatic OSTα/OSTβ is induced under cholestatic conditions both in patients and rodents ([@b0175; @b0275]) its pathogenetic role in liver diseases remains poorly understood. Notably, OSTα deficiency in mice resulted in a reduced BS pool size and impaired cholesterol absorption without development of cholestatic phenotype or liver damage ([@b0115; @b1265]). Furthermore, experimental models of obstructive cholestasis and dietary BS supplementation showed attenuated liver injury in *OSTα*^−/−^ mice through involvement of adaptive mechanisms in liver (phase I and II detoxification, phase III elimination through MRP4) and augmentation of renal BS excretion ([@b0295; @b1405; @b1410]). In addition to the above mentioned mechanisms, OSTα deficiency reduced BS pool size through retention of BSs in enterocytes and BS-FXR-fibroblast growth factor 15 (FGF15)-mediated inhibition of hepatic *CYP7A1* (the rate-limiting enzyme in BS synthesis) ([@b0855; @b0860; @b1410]). Whether OSTα/OSTβ dysfunction may cause elevation of serum cholesterol levels and promote development of gallstone disease due to FGF19 (human orthologue of FGF15)-mediated inhibition of cholesterol utilization and decreased biliary excretion remains to be explored in detail. However, non-obese female gallstone patients had reduced intestinal OSTα/OSTβ mRNA as well as protein levels, which correlated with lower expression of *FXR* and its other targets apical sodium-dependent bile acid transporter (*ASBT*) and *FGF19* ([@b1285]). Given the fact that *OSTα*/*OSTβ* induction in liver will promote basolateral BS elimination, whereas its inhibition in gut will reduce BS pool size (through decreased absorption and synthesis), organ-specific modulation of OST-mediated BS transport appears to be an attractive therapeutic concept in cholestasis.

5. Transcriptional regulation of OSTα/OSTβ {#s0025}
==========================================

OST-mediated BS transport requires co-expression of both subunits by 2 distinct genes: *OSTα* and *OSTβ* ([@b0285; @b1335; @b1585]). Importantly, coexpression and heterodimerization of OSTα and OSTβ subunits and their mutual interaction enables the proper function of the transporter ([@b0285; @b1335]). Specifically, normal OSTα gene and protein expression are critical for the proper function of OSTβ ([@b0925; @b1265; @b1485]), whereas OSTβ promotes trafficking of OSTα to the cell membrane and its functional activity ([@b0260; @b1585]). Since OSTα and OSTβ protein levels correlate with respective transporter mRNA levels in human ileal biopsies, OSTα/OSTβ is believed to be regulated mainly at the transcriptional level ([@b1285]). The key role of BS-FXR-mediated mechanism of *OSTα*/*OSTβ* gene regulation was uncovered in mice deficient in the ileal BS uptake transporter ASBT (*ASBT*^−/−^ mice) ([@b0285]). Interestingly, blockade of BS uptake in ileum repressed *OSTα*/*OSTβ* expression in this part of the gut, whereas its expression in colon was induced due to high transporter-independent intracellular BS flux ([@b0285]). Indeed, *OSTα*/*OSTβ* gene transcription is directly controlled by FXR in human and mouse tissues ([@b0865; @b0900]) and loss of *FXR* abolished *OSTα*/*OSTβ* induction by CA feeding ([@b1730]b). Two functional FXR-binding sites have been identified in the human *OSTα* and one in the *OSTβ* gene promoter ([@b0865]). Moreover, human *OSTα*/*OSTβ* is also induced by GR, whereas vitamin D receptor (VDR/NR1I1) and PXR are unlikely to play a key regulatory role for the human transporter ([@b0745]). Of note, mouse *OSTα*/*OSTβ* gene expression may be induced by the liver X receptor (LXR/NR1H3) through binding to the elements of FXRE IR-1 ([@b1145]). In contrast, LRH-1 is responsible for negative regulation of mouse *OSTα*/*OSTβ* expression in response to BSs ([@b0390]). However, positive *OSTα*/*OSTβ* regulation by FXR appears to be dominant and LRH-1 is unlikely to play a critical role in baseline expression of OST transporters. Collectively, these findings suggest that FXR and GR ligands could have therapeutic potential to induce OSTα/OSTβ-mediated basolateral BS export from hepatocytes in humans.

6. Functional role of NTCP in health and disease {#s0030}
================================================

During their enterohepatic circulation, approximately 95% of biliary BSs are efficiently reabsorbed in intestine and return to liver where they are taken up by hepatocytes and undergo a further cycle of biliary excretion and subsequent enterohepatic circulation ([@b0600]). Hepatic uptake of BSs takes place against a 5--10-fold concentration gradient at the basolateral surface of hepatocytes and is mediated through the Na^+^-taurocholate co-transporting polypeptide (NTCP/SLC10A1) ([@b0030; @b0515; @b1445]) and a group of Na^+^-independent organic anion transporting polypeptides (OATPs) ([@b1100]). NTCP mediates Na^+^-dependent uptake of all physiological BSs in their conjugated form ([@b1445]), estrone-3-sulphate, thyroid hormones ([@b1015]) and drugs bound to TCA, e.g., chlorambucil-taurocholate ([@b0815]). In contrast to NTCP OATPs have a lower affinity for BSs (Na^+^-independent transport) and broader substrate specificity ([@b0770; @b0820]).

Although no mutations of NTCP have been identified as primary causative factor for human cholestasis, the *NTCP* variant Ser267Phe in Chinese-Americans showed a near complete loss of function of BS transport with preserved uptake of other substrates, thereby uncovering the critical role of this region for BS recognition ([@b0585]). Furthermore, dependent on substrate specificity, NTCP variants may significantly impair the uptake of TCA and drugs such as statins, thereby limiting their clinical effectiveness ([@b0250; @b1165]). *NTCP* gene expression is reduced in human cholestatic conditions such as biliary atresia, advanced primary biliary cirrhosis (PBC) and cholestatic alcoholic liver injury ([@b1360; @b1710; @b1705]) as well as in several cholestatic animal models ([@b0415; @b0885; @b1530; @b1715]). However, the pathophysiological role of altered *NTCP* expression in cholestasis remains unclear. Nevertheless, *NTCP* repression may contribute to impairment of bile formation, although this mechanism appears to reflect hepatocyte adaptation to increased intracellular BS levels.

7. Transcriptional regulation of NTCP {#s0035}
=====================================

Repression of *NTCP* in response to BS challenge in normal/pathologic conditions is an important step in protection against intracellular BS overload since the majority of BSs excreted into bile are derived from the enterohepatic circulation. NTCP regulation differs considerably between species. Studies in knock-out or overexpression animal models identified the key transcriptional regulators of rodent *NTCP* such as homeodomain protein hepatocyte nuclear factor 1 alpha (HNF-1α), hepatocyte nuclear factor 4 alpha (HNF-4α), RXRα, hepatocyte nuclear factor-3β (HNF-3β) and FXR/SHP ([@b0300; @b0555; @b0670; @b0710; @b0890; @b1270; @b1355]). Despite virtually absent baseline *NTCP* expression in models of HNF-1α deficiency and deficiency of the binding site for retinoic acid receptor alpha (RARα/NR1B1/RXRα heterodimer, no respective response element was found in the minimal promoter of mouse *NTCP* ([@b0425]b; [@b0685]b). In contrast, HNF-4α directly binds to the murine *NTCP* promoter through functional HNF-4α-response element ([@b0440]) and PGC-1α potentiates *NTCP* transactivation by HNF-4α. Since HNF-1α controls HNF-4α transcription, repressed *NTCP* expression in HNF-1α deficiency may reflect potentially HNF-4α-mediated mechanism ([@b0530; @b1130]). Importantly, the human *NTCP* promoter is devoid of a TATA regulatory box ([@b1350]), which explains the absence of binding sites for respective transcriptional factors regulating murine *NTCP*. Among the known binding sites of *NTCP* promoter only the HNF-3β response element is shared by the mouse, rat and human sequence ([@b0685]b). Human *NTCP* is also positively regulated by the GR, for which PGC-1α and components of co-activating complex ASCOM act as co-activators ([@b0045]). In addition, cAMP response element members of the CCAAT/enhancer-binding protein (C/EBP) family were able to transactivate human *NTCP* ([@b0685]b; [@b1350]), whereas C/EBP mutations reduced *NTC*P expression by 70% ([@b1350]).

Negative feedback regulation of murine *NTCP* by BSs is mediated through FXR-SHP-mediated prevention of its positive regulation by RXRα/RARα ([@b0300]) or competition of SHP with co-activators for binding to HNF-4α and RXRα ([@b0890]), whereas SHP-mediated negative interaction with GR and PGC-1α represent the main molecular mechanisms mediating BS-dependent repression of human *NTCP* ([@b0335]). Notably, CA feeding repressed *NTCP* expression in *SHP*^−/−^ mice, indicating that SHP-independent mechanisms may also be involved in mediating *NTCP* repression in cholestasis ([@b1595]). Since BSs inhibit human HNF-1α activation by HNF-4α in SHP-independent manner ([@b0670]), this mechanism is also likely to be involved in NTCP repression in mice. In addition to BS-mediated mechanisms, endotoxin/cytokine-mediated inhibition of main *NTCP* regulators RARα/RXRα, HNF-4α and HNF-1α or their binding activity may also contribute to *NTCP* repression in cholestasis ([@b0145; @b0430; @b0425; @b0505; @b0545; @b1085; @b1090; @b1530]). Inhibition of c-Jun N-terminal kinase (JNK)-mediated RXRα phosphorylation is involved in reduced RARα/RXRα binding activity and *NTCP* downregulation by Il-1β ([@b0920]). In line with rodent data, IL-1β also suppressed human *NTCP* transcription and protein levels ([@b0880]). However, cytokine inactivation or Kupffer cell depletion failed to restore inhibition of *NTCP* gene expression in mice ([@b0435]b). In line with these findings, decreased nuclear HNF-1α and HNF4α protein levels and inhibited HNF-1α binding activity were also not restored after cytokine inactivation in CBDL ([@b0435]b). Furthermore, reduced levels of the key regulators (HNF-1α, HNF-4α, RXR/RARα) did not differ between *FXR^+^*^/^*^+^* and *FXR*^−/−^ mice after CBDL or LCA feeding, despite pronounced difference in *NTCP* expression ([@b1720]). These findings indicate that BS-mediated mechanisms, but not cytokines play the predominant role in downregulation of *NTCP* in cholestasis ([@b0430]b).

Finally, sex hormones also play an important role in regulation of *NTCP* gene expression as demonstrated by 2-fold higher expression in male compared with female rats. *NTCP* expression was repressed in pregnant female animals or after estradiol administration in males ([@b0060; @b0170; @b0420; @b1370]), while ovarectomy resulted in increased *NTCP* expression in females ([@b1375]). These data provides a potential molecular mechanism for sex hormone-induced cholestasis. Importantly, models of experimental hypophysectomy provided evidence for the role of the complex interplay of pituitary hormones in regulating *NTCP* expression by sex hormones ([@b1375]). The pituitary gland hormone prolactin facilitates *NTCP* transcription through prolactin receptor-mediated binding of signal transducers and activators of transcription (STAT-5) to its two binding sites in the rat *NTCP* promoter ([@b0410]), whereas estradiol repressed PLR-induced *NTCP* upregulation in human cells ([@b0200]). Similarly, a STAT-5-mediated mechanism is involved in growth hormone-mediated upregulation of rat *NTCP* ([@b0195]).

Taken together, transcriptional regulation of the main hepatobiliary BS transporters *BSEP*, *OSTα*/*β* and *NTCP* play an important role in cholestatic liver disease. The key positive and negative transcriptional regulators of human BSEP, OSTα/OSTβ and NTCP are summarized in [Table 1](#t0005){ref-type="table"}.

8. Novel therapeutic strategies targeting transcription factors in cholestasis {#s0040}
==============================================================================

Pharmacological stimulation of canalicular BS efflux through BSEP and basolateral elimination through OSTα/OSTβ or inhibition of hepatocellular BS uptake through NTCP *via* targeted stimulation of the key regulatory transcription factors may have important clinical applications and represents a promising direction for novel drug development in cholestasis. Several traditional drugs widely used to treat cholestatic liver disorders have turned out to act at least in part through activation of transcription factors regulating hepatobiliary transport and metabolism. Moreover, key regulatory transcription factors have also become the focus of targeted therapies in cholestasis.

8.1. Ursodeoxycholic acid and derivatives {#s0045}
-----------------------------------------

Currently, pharmacological therapy of cholestatic liver diseases is limited to use of ursodeoxycholic acid (3α,7β-dihydroxy-5β-cholanoic acid or UDCA), which represents 1--3% of total BSs in human bile ([@b0595]). Importantly, UDCA does not activate FXR ([@b0955; @b1170; @b1310]), but binds to GR (discussed below) ([@b1060]) and is capable of activating PXR after its transformation to LCA by intestinal flora ([@b1425; @b1635]). Anti-cholestatic effects of this drug are mediated through induction of BS-dependent as well as BS-independent bile secretion by several mechanisms ([@b0665; @b1205; @b1245; @b1525]). These include induction of *BSEP* and *MRP2* on the transcriptional level in mice ([@b0370]) as well as posttranscriptional mechanisms influencing vesicular transport, exocytosis and membrane insertion ([@b0160; @b0320; @b0800; @b0835; @b1040]). Interestingly, despite increased BSEP protein levels *BSEP* mRNA remained unchanged in non-cholestatic gallstone patients after UDCA administration, indicating that predominantly posttranscriptional mechanisms are involved ([@b0970]). In addition, UDCA restored pathologically reduced expression of the biliary $\text{HCO}_{3}^{-}$ exchange transporter anion exchanger 2 (*AE2*/*SLC4A2*) in PBC patients ([@b1005; @b1255]) and its combination with glucocorticoids synergetically induced *AE2* alternate promoter in human cells ([@b0055]). Furthermore, UDCA also has several immunomodulatory effects *in vitro* ([@b0840; @b1115; @b1655; @b1675]). These pleiotropic mechanisms may explain the beneficial clinical effects of UDCA in a broad range of cholestatic disorders including PBC (biochemical and histological improvement and prolonged survival without liver transplantation) ([@b0875; @b1205; @b1235; @b1240; @b1230]) and ICP (improved maternal pruritus, serum transaminases as well as neonatal outcomes) ([@b0080; @b0180; @b0470; @b0475; @b0765; @b0995; @b1155]). However, standard doses of UDCA did not improve survival in primary sclerosing cholangitis (PSC) and high dose UDCA was even associated with higher risk of severe side effects and mortality ([@b0940]).

A side chain shortened derivative of UDCA, 24-*nor*UDCA reduced serum liver enzymes, induced bile flow and improved hepatic inflammation and fibrosis in *MDR2*^−/−^ (*ABCB4*^−/−^) model of sclerosing cholangitis ([@b0375]). Beneficial effects of 24-*nor*UDCA in this model of liver injury were associated with coordinated induction of BS detoxification (through *CYP2B10*, *CYP3A11* and *SULT2A1*) and basolateral export through alternative transporters *MRP3* and *MRP4* on transcriptional level without significant effects on *BSEP* or *NTCP* gene expression ([@b0375]). Importantly, in comparison with UDCA, 24-*nor*UDCA is more resistant to amidation, which may promote its cholehepatic shunting and thereby contribute to increased secretion of protective $\text{HCO}_{3}^{-}$. Clinical trials with 24-*nor*UDCA for PSC have been already initiated and the results of a phase II randomized double-blind multi-center placebo-controlled study will provide first answers about clinical efficacy of this promising compound.

Importantly, derivatives of 24-*nor*UDCA tauro-*nor*UDCA and di-*nor*UDCA do not share pharmacological properties of 24-*nor*UDCA and failed to improve liver injury in the *MDR2*^−/−^ model. Moreover, di-*nor*UDCA even worsened liver injury, underlining the unique beneficial properties of 24-*nor*UDCA due to its resistance to amidation and cholehepatic shunting ([@b0520]).

8.2. Therapeutic potential of FXR activators {#s0050}
--------------------------------------------

Since FXR represents a master regulator of BS homeostasis and inflammation by targeting a broad spectrum of molecular mechanisms ([@b1065; @b1535; @b1565; @b1600]) its pharmacological activation may exert multiple protective mechanisms in cholestasis. The main mechanisms by which FXR activation may protect against cholestatic liver injury are summarized in [Table 2](#t0010){ref-type="table"}. A significant proportion of FXR's therapeutic effects in cholestasis may be due to the fact that FXR regulates gene expression of the key BS transporters including uptake transporter NTCP and export transporters BSEP and OSTα/OSTβ in addition to promoting BS detoxification through phase I hydroxylation by CYP3A4 ([@b0480]), phase II sulfoconjugation by SULT2A1 ([@b1395]) and glucoconjugation by UGT2B4 ([@b0125]). Thus, FXR activation by high affinity agonists with no side effects may represent an attractive therapeutic concept in cholestasis. Non-steroidal compounds GW4064, FXR-450 or WAY-362450 and PX20350 are potent FXR activators ([@b0005; @b0960; @b1010; @b1215]). GW4064 induced *BSEP*, *SHP*, *MRP2* and *MDR2*, inhibited *NTCP*, repressed BS synthesis and showed hepatoprotective effects in rat models of intrahepatic (alpha-naphthylisothiiocyanate administration) and extrahepatic (CBDL) cholestasis ([@b0945]). Furthermore, GW4064 induced BS-independent bile secretion in human gallbladder through FXR-mediated induction of vasoactive intestinal peptide receptor 1 (VPAC1) transcription, the major regulator of bile secretion ([@b0240]). A recent study showed that GW4064 and PX20350 may also prevent/treat hepatocellular carcinomas through FXR-dependent induction of tumor suppressor gene NMYC downstrean-regulated gene 2 (NDRG2) ([@b0305]). The currently available ligands for clinical trials represent chemical modifications of endogenous BSs ([Table 3](#t0015){ref-type="table"}). Specifically, a semi-synthetic obeticholic acid (OCA) also known as 6-ethylchenodeoxycholic acid (6-ECDCA) or INT-747 was synthesized on the basis of CDCA backbone and is an approximately 100-fold more potent FXR activator ([@b1215]). OCA was beneficial in animal models of LCA-, estrogen-, carbone tetrachloride (CCl4)- or CBDL-induced cholestasis ([@b0380; @b1215]). It is important to consider that in contrast to these models of liver injury, dietary OCA supplementation deteriorated liver injury in the *MDR2*^−/−^ model despite its strong FXR activating capacity ([@b0095]). Since biliary secretion of protective PLs is absent in *MDR2*^−/−^ mice (corresponding to liver disease from *MDR3* mutations in humans), increased biliary excretion of hydrophobic OCA and concominant reduction of endogenous BSs (in mice mainly in form of more hydrophilic muricholic acid) could result in a net increase of more hydrophobic BS proportion in bile, thereby promoting liver injury in this specific model. Recent clinical trials have shown beneficial effects of OCA treatment in patients with PBC. Short- and long-term combination of OCA with UDCA reduced serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels in PBC patients biochemically not responding to UDCA treatment ([@b0580; @b0980]). Moreover, OCA monotherapy significantly reduced serum ALT, ALP and gamma-glutamyl transpeptidase (GGT) levels in treatment-naive PBC patients ([@b0775]). Itching was the most common adverse effect in patients receiving high dose OCA treatment. A phase III, double blind, placebo controlled trial and long term safety study of low-dose OCA treatment has been initiated in PBC patients.

Further modifications of OCA led to synthesis of a semi-synthetic 23-sulfate-derivative 6α-ethyl-3α,7α,23-trihydroxy-24-nor-5β-cholan-23-sulfate sodium salt also called INT-767 ([@b1290]). In contrast to OCA, INT-767 is a hydrophilic compound with higher affinity to FXR. In addition, INT-767 may also activate the membrane BS receptor TGR5/GPBAR1 ([@b1290]). Importantly, INT-767 significantly reduced serum ALT levels, decreased portal inflammation and biliary fibrosis in the *MDR2*^−/−^ animal model of sclerosing cholangitis ([@b0095]). These beneficial effects were mediated by several FXR-dependent hepatoprotective mechanisms including induction of *BSEP* mRNA and protein levels, promotion of BS-independent bile flow through promotion of protective $\text{HCO}_{3}^{-}$ secretion with simultaneous inhibition of BS synthesis and *NTCP* repression. Altogether, INT-767 treatment resulted in lower BS and higher $\text{HCO}_{3}^{-}$ output into bile. In addition, since INT-767 may also act as a potent activator of the membrane BS receptor TGR5, it may also induce bile secretory function though non-transcriptional cAMP signaling pathways ([@b0720; @b0975]). Thus, INT-767 represents a very promising new drug to treat non-obstructive cholestasis in humans. However, TGR5 expression is induced in cholangiocellular carcinoma, where it may confer resistance to apoptosis ([@b0730]), indicating that ligands which can also activate TGR5 have to be seen with some caution.

Notably, FXR activation induces hepatocellular proliferation in animal models ([@b0095; @b0640]) which theoretically may raise concerns in regards to risk for tumor development. However, FXR directly regulates tumor suppressor *NDRG2* ([@b0305]) and may also prevent tumor development *via* its anti-inflammatory properties. Conversely, *FXR* and *BSEP* expression is reduced in hepatocellular ([@b0235; @b1470]). Finally, stimulation of bile flow may have critical deleterious effects in obstructive cholestasis ([@b1430; @b1555; @b1710]). Therefore, preserved biliary drainage will be necessary to fully achieve beneficial effects of FXR activators. However, since FXR is expressed in almost all tissues and regulates a broad range of metabolic pathways FXR ligands are likely to have several additional metabolic off-target effects. Finally, endogenous BSs as well as hepatobiliary transport systems differ considerably between species, which makes it difficult to predict the undesired effects of FXR activation in humans based on animal studies. Thus, carefully designed clinical studies are required to answer all these open questions.

Since frequent BSEP mutations are associated with impaired trafficking of BSEP from the ER to the plasma membrane, pharmaceutical targeting of post-transcriptional regulatory mechanisms represents another promising approach to reduce cholestasis (discussed in detail in chapter by J.L. Boyer). Interestingly, the natural ligands/substrates of BSEP, BSs, arise as perfect candidates to act as pharmacological chaperones promoting proper folding and trafficking of mutated BSEP ([@b1055]). Novel derivatives of GW4064 compound enhanced BSEP transport activity through their function as chaperons and the 7c analog of the reverse-amide GW4064 derivative has been identified as selective BSEP function enhancer ([@b1050; @b1055]). Thus, separation of FXR-agonistic activity from BSEP function-enhancing activity will help to selectively target cholestatic liver injury without broad metabolic effects of FXR.

8.3. Therapeutic potential of CAR and PXR {#s0055}
-----------------------------------------

In obstructive cholestasis, detoxification and basolateral elimination of BSs without induction of canalicular secretion may be critical. Genes encoding hepatocellular drug metabolizing enzymes and alternative transporters are direct targets of nuclear receptors such as constitutive androstane receptor (CAR/NR1I3) and PXR (NR1I2) ([@b0225; @b0230; @b0365; @b0445; @b0495; @b0490; @b1105]), establishing a substantial role of these transcriptional factors in defense against toxic liver injury ([@b1725]a). In addition to stimulating bilirubin clearance ([@b0220; @b0625; @b0630; @b0715]) and BS detoxification ([@b0620; @b1305; @b1475]) CAR activation promotes MRP4-mediated basolateral elimination of BSs ([@b0215]). Importantly, CAR ligands phenobarbital and a component from *Artemisia capillaris* (dimethylesculetin) which is used in Chinese herbal teas Yin Zhi Huang and Yin Chin efficiently reduced pruritus and neonatal jaundice ([@b0070; @b0165; @b0630; @b1455]). However, CAR activation was hepatotoxic in mice despite significant reduction of serum BS and bilirubin levels ([@b1560; @b1660]). Furthermore, CAR ligands promoted hepatic tumor development ([@b0605; @b0635; @b0750; @b1640]) through upregulation of the anti-apoptotic effector myeloid cell leukemia factor 1 (*MCL-1*) gene expression ([@b0140; @b1075]).

Apart from CAR, PXR may also be beneficial in cholestasis by induction of BS hydroxylation ([@b0970; @b1630]), inhibition of BS synthesis ([@b1420]) and bilirubin clearance ([@b0220; @b0625; @b0630; @b0715]) as well as inhibition of serum cholestatic enzyme autotaxin activity ([@b0785; @b0790]). PXR ligand rifampicin improved pruritus in cholestatic patients ([@b0070; @b0190; @b1670]) and reduced serum liver enzymes in PBC and animal models of liver injury ([@b1420; @b1505; @b1510; @b1635]). However, rifampicin therapy may be associated with development of hepatitis and an increase of serum liver enzymes in 7% of patients ([@b0075; @b1260]). Apart from these undesired effects, induction of drug-metabolizing enzymes by CAR or PXR may induce generation of reactive metabolites and have critical importance for drug interactions ([@b0485; @b1045]). Together, these findings indicate that despite desired induction of BS detoxification and elimination mechanisms, CAR and PXR activation is associated with the risk of tissue damage and tumor development. Therefore, ligands of these transcriptional regulators, if strongly indicated, may be administered only for a short-term treatment. Furthermore, CAR antagonists may represent an interesting strategy to treat oxidative stress-mediated liver injury in humans ([@b0810]). However, further studies are required to establish the biological role of CAR inhibition in health and disease.

8.4. Therapeutic potential of GR, PPARα, PPARγ and VDR {#s0060}
------------------------------------------------------

In addition to FXR, CAR and PXR there is arising evidence for the role of additional transcriptional factors such as GR, peroxisome proliferator-activated receptors alpha (PPARα/NR1C1) and gamma (PPARγ/NR1C3) and VDR in cholestasis. Glucocorticoids, which are widely used in clinical practice due to their pronounced immunosuppressive action, but may also play an important role in cholestasis through transcriptional regulation of BS transporters *NTCP*, *ASBT* and *OSTα*/*OSTβ* ([@b0335; @b0680]a; [@b0745]). Moreover, GR may interact with other transcription factors such as CAR, PXR and RXRα leading to synergetic stimulation of target gene expression ([@b1175; @b1180; @b1480; @b1700]).

Combination therapy of UDCA with glucocorticoids induced $\text{HCO}_{3}^{-}$ transporter *AE2* gene expression in PBC ([@b0055; @b1000; @b1005; @b1235; @b1250]), which may also explain stimulation of bile secretion in patients with biliary atresia after Kasai operation ([@b1035]) and $\text{HCO}_{3}$-dependent bile flow in rats ([@b0025]). Compared with UDCA monotherapy combination of budesonide (a glucocorticoid with low adverse effects) with UDCA was more efficient with respect to reduction of serum liver enzymes and liver histology in early stage PBC ([@b0910; @b1275]). However, budesonide monotherapy showed severe side effects and increase in Mayo risk score in UDCA non-responders ([@b0050]). Furthermore, budesonide treatment in stage 4 PBC patients was associated with portal vein thrombosis and death, thereby establishing an absolute contraindication for budesonide use in late-stage PBC ([@b0570]). Notably, GR activation inhibited FXR transcriptional activity and led to cholestasis through recruitment of C-terminal binding protein (CtBP) co-repressor complexes and subsequent induction of BS synthesis and repression of hepatocellular transporters in mice ([@b0950]). Furthermore, suppressed expression of FXR and FXR target genes by glucocorticoids ([@b1300]) may contribute to development of cholestasis as demonsrated by increased serum BS levels in patients with Cushing syndrome ([@b0950; @b1650]). Interestingly, UDCA effects are partially mediated through GR activation ([@b1490; @b1495]). Interaction of UDCA with a specific part of the GR ligand-binding domain leads to loss of specific co-activator recruitment and subsequently weak induction of glucocorticoid response element (GRE) gene response while strongly inhibiting NF-κB target genes ([@b1060]). Thus, dissociation of GR-dependent transcription of selective targets by UDCA may represent a very promising starting point for development of novel drugs with less undesired effects.

Agonists of PPARα, which are widely used as antihyperlipidemic drugs, can induce hepatic detoxification ([@b0120; @b0345; @b0610]) and promote MDR3-mediated canalicular PL secretion ([@b0460; @b0990; @b1295; @b1365]), modify intestinal BS uptake ([@b0675]) and inhibit BS synthesis ([@b0965; @b1190; @b1225]). Unlike CAR and PXR, direct induction of mitochondrial uncoupling protein 2 gene (UCP2) expression ([@b1195]) by PPARα may be protective against reactive metabolites and therefore might have a potential in the treatment of BS- and drug-induced toxicity. Indeed, combination of UDCA with PPARα agonists bezafibrate and fenofibrate improved serum liver tests in PBC patients with incomplete biochemical response to UDCA ([@b0205; @b0610; @b0645; @b0705; @b0915; @b1095]) and even showed histological improvement as monotherapy ([@b0830; @b0825; @b1665]). Since these studies have been conducted in a small number of patients and mainly after a short-term treatment, additional longer treatment studies with higher patient numbers are required to establish the long-term efficacy and safety of fibrate treatment in PBC.

In contrast to PPARα, PPARγ plays an important role for cholangiocyte injury ([@b0540]) and is critical for the maintenance of a quiescent state of profibrogenic cells ([@b0560; @b0565; @b1340; @b1695]). PPARγ activation in cholangiocytes and portal myofibroblasts by curcumin improved liver injury and biliary fibrosis in the *MDR2*^−/−^ model of sclerosing cholangitis ([@b0090]). Interestingly, PPARγ ligand rosiglitazone improved LPS-induced liver injury by attenuating cytokine-mediated nuclear export of RXRα and restoring its binding activity in hepatocytes with subsequent induction of *BSEP* and *NTCP* in mice ([@b0465]). Since PPARγ is not expressed in hepatocytes, beneficial effects of rosiglitazone on hepatocellular transporter gene expression *in vivo* and *in vitro* may reflect indirect mechanisms involving potential effects of rosiglitazone metabolites, activation of additional signaling pathways or interaction with cytokines. Importantly, PPARγ agonists showed pronounced side effects and troglitazone was withdrawn from the market due to its hepatotoxic effects, which notably were PPARγ-independent ([@b0400; @b1385]). Since PPARγ is unlikely to influence hepatocellular homeostasis, selective targeting of cholangiocytes and fibrogenic cells by PPARγ activators is likely to have major beneficial effects in portal inflammation and biliary fibrosis ([@b0535]).

Importantly, VDR variants were identified in PBC and autoimmune hepatitis ([@b0340; @b0525; @b1500; @b1550]). They reduced VDR protein levels and were shown to be inversely correlated with histological severity of nonalcoholic steatohepatitis and viral hepatitis C ([@b0130]). However, CDCA-mediated induction of *BSEP* expression was impaired by VDR interaction with FXR *in vitro*, indicating potential undesired effects of VDR activation in BS toxicity ([@b0615]). Given the fact that VDR directly inhibits activation and proliferation of hepatic stellate cells ([@b0010]) and proinflammatory cytokine expression ([@b1140]), VDR activation is likely to improve cholestasis *via* improvement of inflammation and fibrosis but not through direct modulation of hepatic BS transport systems. In addition, induction of antibacterial cathelicidin gene expression by VDR in biliary epithelium may be essential for biliary tract sterility and help to prevent/treat cholangiopathies ([@b0280]). Since limited absorption of fat-soluble vitamins may affect Vitamin D levels in cholestatic patients, VDR activators may also have a beneficial role to prevent/treat osteoporosis in cholestatic patients.

9. Conclusions {#s0065}
==============

Transcriptional regulators of hepatocellular transport systems have emerged as promising drug targets with extraordinary potential in the treatment of cholestatic liver disease. Novel and (compared with endogenous BSs) less toxic FXR activators may counteract cholestasis through induction of biliary and sinusoidal BS export, promotion of BS-dependent and BS-independent bile flow, inhibition of BS synthesis and anti-inflammatory effects. Since FXR has very broad tissue and organ distribution and its activation might also impact on multiple mechanisms regulating glucose and lipid homeostasis, selective *BSEP* or *OSTα*/*OSTβ* inducers (*via* FXR) may represent the future direction for novel FXR-directed drug development. GR activators are predicted to be beneficial to control disease flare and acute inflammation, but long-term glucocorticoid therapy will have critical undesired effects. As an alternative, novel GR agonists with an ability to selectively block the NF-κB signaling and limited or absent side effects may represent a future strategy for GR activation in chronic cholestasis. PXR and CAR agonists, which prevent accumulation of cytotoxic BS by induction of their detoxification and basolateral elimination, represent an attractive treatment strategy in obstructive cholestasis. Nevertheless, clinical use of these ligands might be limited due to potential hepatotoxic and tumor promoting effects. Finally, drug interactions and potential impact of other transcriptional factor/nuclear receptor-directed drugs has to be evaluated in depth to minimize potential adverse effects and improve therapeutic efficiency of novel drugs.
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###### 

Transcriptional regulators of main bile salt transporters *BSEP, OSTα*/*OSTβ* and *NTCP* in humans.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Transporter              Positive regulators                                                                                 Negative regulators
  ------------------------ --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  BSEP/ABCB11              FXR/NR1H4-Co-activators:-PGC-1α-Components of ASCOM complex-Set7/9 methyltransferase-CARM-1-SRC2\   Pro-inflammatory cytokines TNF-α, IL-6 and IL-1β-Inhibition of FXR/RXRα binding activity-Direct interaction of NF-κB with FXR-Repression of RXRα\
                           LRH1/NR5A2-Potentiates FXR-mediated transactivationNRF2\                                            Drugs (e.g., troglitazone)-Stable complex formation with FXR and suppression of FXR-dependent transactivation\
                           PXR/NR1I2                                                                                           Female hormones-β-estradiol

                                                                                                                               

  OSTα/OSTβSLC51A/SLC51B   FXR/NR1H4\                                                                                          Not known
                           GR/NR3C1                                                                                            

                                                                                                                               

  NTCP/SLC10A1             GR/NR3C1\                                                                                           FXR-SHP-mediated negative interaction with RXRα, GR and PGC-1α\
                           Co-activators:-PGC-1α-Components of ASCOM complex\                                                  IL-1β-Reduction of RARα/RXRα binding activity through inhibition of RXRα phosphorylation
                           RARα/RXRαC/EBP                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Molecular targets of FXR in liver and potential beneficial effects of FXR activation in cholestasis.

  Molecular targets of FXR in liver                                                                                                                                                                                                                                                                                                                                                      Effects in cholestasis
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------
  -Canalicular export of BSs through *BSEP* and *MRP2*-Basolateral BS elimination *via OSTα*/*OSTβ*-Inhibition of *NTCP*- and *OATP1B1*-mediated BS uptake-Inhibition of BS synthesis (inhibition of *CYP7A1* through FGF19- and SHP- mediated mechanisms, inhibition of *CYP8B1*and *CYP27A1*)-Promotion of BS detoxification (through upregulation of *CYP3A4*, *SULT2A1*, *UGT2B4*)   Reduction of intracellular BS toxicity
                                                                                                                                                                                                                                                                                                                                                                                         
  -Reduced biliary excretion of BSs through inhibition of synthesis-Canalicular PL secretion through *MDR3* and promotion of mixed micelle formation-Promotion of $\text{HCO}_{3}^{-}$ -rich bile secretion through *carbonic anhydrase 14*-Induction of gallbladder secretion via *VPAC-1*                                                                                              Reduction of bile toxicity
                                                                                                                                                                                                                                                                                                                                                                                         
  -Repression of pro-inflammatory gene expression through interaction with NF-κB                                                                                                                                                                                                                                                                                                         Inhibition of inflammation

###### 

FXR ligands with potential clinical application.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agonist                                                  Clinical application                                                           Comments
  -------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------
  CDCA (Chenofalk TN)                                      Gallstone disease, cerebrotendinous xanthomatosis                              Hepatotoxicity in rhesus monkey, but not in humans

  OCA/6-ECDCA/INT-747 (semisynthetic derivative of CDCA)   PBC, NAFLD/NASH, bile acid diarrhoea, gallstone disease, portal hypertension   Beneficial in combination with UDCA (biochemically non-responders to UDCA) or as monotherapy (treatment-naïve patients) in PBC.\
                                                                                                                                          Dose-dependent pruritus

  INT-767 (synthetic derivative of OCA)                    Preclinical                                                                    Preclinical: biochemical and histological improvement in *MDR2*^−/−^ mouse model of sclerosing cholangitis

  GW4064 (synthetic agonist)                               Preclinical                                                                    Not further developed for clinical use

  FXR-450/WAY-362450 (synthetic agonist)                   NAFLD                                                                          Phase 1 trial in healthy Japanese men was terminated due to pharmacokinetic issues

  PX-104                                                   NAFLD                                                                          Phase 2 trial to assess the safety and tolerability in NAFLD patients
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
